Ira Winer
YOU?
Author Swipe
View article: Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
COXPH model for patients with at least 6-mo overall survival
View article: Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Copy number alterations (CNAs) and fusions among cohort
View article: Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival by RUCA code and poverty
View article: Supplementary Figure S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival of cohort by stage
View article: Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival by RUCA code and poverty
View article: Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Description of rural-urban commuting area (RUCA) codes
View article: Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Prevalence of common mutations in tumor subtypes
View article: Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Comparison of overall survival among chemotherapy-treated TP53-mutated and TP53-wild type patients in Caris CODEai clinico-genomic database
View article: Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
COXPH model for patients with stage information
View article: Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Comparison of Caris cohort data with Puckrein dataset
View article: Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Gene mutations according to poverty level and RUCA codes
View article: Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S2: Figure 7: Mean ± SD concentration versus time profiles of AR (ADC), total antibody, DM4, and DM4-Me after administration of AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.
View article: Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
trial protocol
View article: Data from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Data from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Purpose:Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assesse…
View article: Supplementary Table S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Representativeness of Study Participants
View article: Supplementary Table S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
: Pharmacokinetic parameters of AR after administration of 2.2 mg/kg AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.
View article: Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Treatment-related AEs (Any grade)
View article: Supplementary Figure S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S3. Relationship between anetumab ravtansine AUC0-inf (A) and DM4 AUC0-168h (B) and best antitumor response.
View article: Supplementary Figure S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S1: Study Scheme
View article: Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer Open
Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. W…
View article: Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Purpose: Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assess…
View article: Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1) Open
Background Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating CD8 + T cells and natural killer cells, with minimal…
View article: Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Prevalence of common mutations in tumor subtypes
View article: Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Gene mutations according to poverty level and RUCA codes
View article: Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Comparison of overall survival among chemotherapy-treated TP53-mutated and TP53-wild type patients in Caris CODEai clinico-genomic database
View article: Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Copy number alterations (CNAs) and fusions among cohort
View article: Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Description of rural-urban commuting area (RUCA) codes